{"id":576732,"date":"2018-06-05T00:00:00","date_gmt":"2018-06-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0004-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-special-topics-car-t-wave-2-us\/"},"modified":"2026-03-31T10:48:24","modified_gmt":"2026-03-31T10:48:24","slug":"sptoon0004-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-special-topics-car-t-wave-2-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0004-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-special-topics-car-t-wave-2-us\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Special Topics | CAR-T | Wave 2 | US | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed\/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this series of reports, we present a comprehensive analysis of current and emerging chimeric antigen receptor (CAR) T-cell therapies. We examine the CAR T-cell treatment landscape: the technology behind it, ongoing clinical development, the challenges, pricing and market access, physicians\u2019 views, and future opportunities for this paradigm-shifting treatment approach.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How is CAR T-cell therapy being adopted into medical practice? What kind of referral patterns are in place for potentially eligible patients? What is the typical patient journey for a patient receiving CAR T-cell therapy?<\/li>\n<li>What kind of support and training programs for Kymriah and Yescarta are in place for healthcare professionals, patients, and caregivers?<\/li>\n<li>What are the key pricing, access, and reimbursement issues facing Kymriah and Yescarta? What novel reimbursement strategies are marketers implementing to ensure market access?<\/li>\n<li>What challenges remain and could limit widespread and maximum adoption of autologous CD19-targeted CAR T-cell therapies? What are the future directions and opportunities?<\/li>\n<li>What are the notable developments in the pipeline? Who are the key players, and what novel targets are they exploring?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Special Topics Report Series: Is a three-wave series based on KOL interviews conducted at about one, six, and twelve months postcommercialization and on secondary data collected from a variety of sources. We capture physicians\u2019 awareness, perception, and use of the launched product and anticipated future trends.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Primary research: <\/strong> Qualitative interviews with\u00a0ten U.S. hematologist-oncologists and thought leaders for the three waves.<\/p>\n<p><strong>Key metrics included:<\/strong><\/p>\n<ul>\n<li>Physician familiarity with and impressions of Kymriah, Yescarta, and other CAR T-cell therapies in the pipeline.<\/li>\n<li>Referral patterns, patient journey, and certification of treatment centers.<\/li>\n<li>Current manufacturing and scalability challenges.<\/li>\n<li>Marketing and educational programs for patients, healthcare professionals, and caregivers.<\/li>\n<li>Cost of CAR T-cell therapy and novel pricing and market access strategies.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-576732","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576732\/revisions"}],"predecessor-version":[{"id":577613,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576732\/revisions\/577613"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=576732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}